← Back to Search

Behavioral Intervention

iCanChange E-Intervention for Cannabis Use Disorder (iCC Trial)

N/A
Waitlist Available
Led By Didier Jutras-Aswad, MD, MSc
Research Sponsored by Centre hospitalier de l'Université de Montréal (CHUM)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Diagnosed with any psychotic disorder (e.g., schizophrenia, schizoaffective disorder, bipolar disorder with psychotic features, delusional disorder, psychotic disorder not otherwise specified, brief psychotic disorder, substance-induced psychotic disorder)
Has been followed at an early psychosis clinic for a minimum of 3 months
Timeline
Screening 3 weeks
Treatment Varies
Follow Up (-2-0 (baseline) and week 6, 12 & 24
Awards & highlights

iCC Trial Summary

This trial will test the feasibility of a mobile health e-intervention for young people with psychosis who use cannabis. The goal is to help them set realistic goals for reducing their cannabis use.

Who is the study for?
This trial is for young adults aged 18-35 with early psychosis and cannabis use disorder (CUD) who are willing to try an intervention to reduce or stop their cannabis use. They must understand French or English, be able to give informed consent, have been followed at an early psychosis clinic for at least 3 months, and used cannabis in the past month.Check my eligibility
What is being tested?
The iCanChange (iCC) e-intervention is being tested in this randomized control trial. It's a mobile health tool designed specifically for individuals with both psychosis and CUD. The study aims to see if it's acceptable and feasible for these patients.See study design
What are the potential side effects?
Since iCanChange is a psychological e-intervention rather than a medication, traditional side effects like those seen with drugs aren't expected. However, participants may experience discomfort discussing substance use or emotional distress related to intervention content.

iCC Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with a psychotic disorder.
Select...
I have been attending an early psychosis clinic for at least 3 months.
Select...
I am between 18 and 35 years old.

iCC Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~(-2-0 (baseline) and week 6, 12 & 24
This trial's timeline: 3 weeks for screening, Varies for treatment, and (-2-0 (baseline) and week 6, 12 & 24 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Completion rates
Retention rates
Secondary outcome measures
Acceptability (iCC usage data)
Cannabis Use
Participant satisfaction
+1 more
Other outcome measures
Cannabis use frequency and abstinence
Cannabis-related problems
Confidence in resisting cannabis use
+8 more

iCC Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Experimental: CHAMPS and mEISExperimental Treatment1 Intervention
Brief mobile application-based psychological intervention based on the principles of motivational interviewing (MI) and cognitive behavioural therapy (CBT). This e-intervention will be completed by the participant using a smart phone. There will be up to a maximum of 24 individual sessions (which includes 3 booster sessions) each lasting approximately 10-15 minutes. mEIS: iCC will be administered adjunctively to modified EIS (mEIS), which will include all interventions usually provided through EIS except for any specific psychological interventions (MI, CBT, contingency management) for CUD.
Group II: No Intervention: EIS aloneActive Control1 Intervention
Early intervention services will be offered as per standard of care following EIS for psychosis and CUD guidelines, at participating clinical sites. Any visits and services offered in control arm will be considered 'usual care' and administered either through in-person clinic visits, community visits, phone calls, or video calls. Relevant service information will be collected for study purposes.

Find a Location

Who is running the clinical trial?

Centre hospitalier de l'Université de Montréal (CHUM)Lead Sponsor
365 Previous Clinical Trials
129,177 Total Patients Enrolled
Ministere de la Sante et des Services SociauxOTHER
17 Previous Clinical Trials
78,032 Total Patients Enrolled
Didier Jutras-Aswad, MD, MScPrincipal InvestigatorCentre hospitalier de l'Université de Montréal (CHUM)
1 Previous Clinical Trials
100 Total Patients Enrolled

Media Library

iCanChange (Behavioral Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT05310981 — N/A
Cannabis Use Disorder Research Study Groups: Experimental: CHAMPS and mEIS, No Intervention: EIS alone
Cannabis Use Disorder Clinical Trial 2023: iCanChange Highlights & Side Effects. Trial Name: NCT05310981 — N/A
iCanChange (Behavioral Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05310981 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is enrollment for this investigation open to new participants?

"The current data on clinicaltrials.gov indicates that this particular medical trial is not currently enrolling patients. It was first uploaded to the database on March 31st 2022 and has maintained its status since then, but there are still 118 other trials actively looking for participants at present."

Answered by AI

What goals is this research endeavor attempting to accomplish?

"The primary outcome of this experiment, assessed over 12 weeks, is retention rates. Secondary objectives comprise cannabis use (quantity and frequency captured via the Timeline Follow Back tool), participant satisfaction (measured by a modified version of the CSQ-8 questionnaire) and acceptability (number of iCC modules completed)."

Answered by AI

Are participants aged 55 or over being accepted in this experiment?

"This medical trial seeks patients aged 18-35 to enroll in the study. Furthermore, there are 15 studies available for minors and 48 trials open to individuals 65 years of age or older."

Answered by AI

What is the geographic breadth of this research project?

"Across Canada, 5 sites are actively recruiting patients for this medical trial. Locations include Nova Scotia Early Psychosis Program in Halifax, Clinic Connec-T - Institut universitaire en santé mentale de Montréal in Montreal, and Clinique JAP, Centre hospitalier de l'Université de Montréal in Quebec City as well as other locations throughout the country."

Answered by AI

Is it possible for me to partake in this experiment?

"This research effort focuses on individuals aged 18 to 35 with a cannabis use disorder, and approximately 100 participants are needed."

Answered by AI
~0 spots leftby Mar 2024